Omnicell/OMCL

$27.93

2.49%
-
1D1W1MYTD1YMAX

About Omnicell

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. The Company's point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company's Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility's in-house information management systems. The Company's Central Pharmacy IV Compounding Service offers a range of service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.

Ticker

OMCL

Sector

Healthcare

Trading on

NASDAQ

Industry

Software & Programming

CEO

Randall Lipps

Employees

3,890

Headquarters

Fort worth, United States

Omnicell Metrics

BasicAdvanced
$1.24B
Market cap
-
P/E ratio
-$0.45
EPS
0.75
Beta
-
Dividend rate

What the Analysts think about Omnicell

Analyst Ratings

Majority rating from 9 analysts.
Hold

Price Targets

Average projection from 7 analysts.
20.19% upside
High $40.00
Low $26.00
$27.93
Current price
$33.57
Average price target

Omnicell Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5.52% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$258.8M
-13.33%
Net income
$-14.3M
-360%
Profit margin
-5.52%
-400%

Omnicell Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 115.22%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.39
$0.57
$0.62
$0.33
-
Expected
$0.07
$0.28
$0.47
$0.15
-$0.09
Surprise
475.41%
101.97%
33.13%
115.22%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Omnicell stock

Buy or sell Omnicell stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing